NCT04448873View on ClinicalTrials.gov

Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

February 1, 2023

Study Completion Date

July 1, 2023

Conditions
Kaposiform HemangioendotheliomaKasabach-Merritt Syndrome
Interventions
DRUG

Sirolimus

After at least 2 years of remission of KHE, we compare guided discontinuation with maintenance treatment in pediatric patients with KHE.

Trial Locations (1)

210012

Children's Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Children's Hospital of Fudan University

OTHER

NCT04448873 - Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma | Biotech Hunter | Biotech Hunter